tiprankstipranks
Trending News
More News >

Penumbra Amends Incorporation Certificate After Stockholder Vote

Story Highlights
  • Penumbra filed an Amended and Restated Certificate of Incorporation on May 28, 2025.
  • Stockholders approved governance changes, including board declassification and eliminating supermajority voting.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Penumbra Amends Incorporation Certificate After Stockholder Vote

Confident Investing Starts Here:

Penumbra ( (PEN) ) has provided an update.

On May 28, 2025, Penumbra, Inc. filed an Amended and Restated Certificate of Incorporation with the State of Delaware, following stockholder approval at its Annual Meeting. During the meeting, stockholders voted on several proposals, including the election of Class I directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation. Additionally, amendments to the company’s charter were approved to phase in board declassification and eliminate supermajority voting requirements, reflecting significant governance changes aimed at enhancing corporate flexibility and shareholder influence.

The most recent analyst rating on (PEN) stock is a Buy with a $232.00 price target. To see the full list of analyst forecasts on Penumbra stock, see the PEN Stock Forecast page.

Spark’s Take on PEN Stock

According to Spark, TipRanks’ AI Analyst, PEN is a Outperform.

Penumbra’s overall stock score reflects strong financial performance with notable revenue and margin growth, primarily driven by its U.S. thrombectomy business. However, the high P/E ratio suggests potential overvaluation, and short-term technical indicators point to possible weakness. The earnings call provided positive growth insights but also highlighted challenges in international markets. These factors collectively contribute to a balanced overall score.

To see Spark’s full report on PEN stock, click here.

More about Penumbra

Penumbra, Inc. operates in the medical device industry, focusing on innovative therapies for neuro and vascular conditions. The company is known for its development of products that address challenging medical conditions, with a market focus on improving patient outcomes through advanced technology.

Average Trading Volume: 513,199

Technical Sentiment Signal: Buy

Current Market Cap: $10.28B

See more insights into PEN stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App